Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07303907
PHASE2
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Sponsor: Definium Therapeutics US, Inc.
View on ClinicalTrials.gov
Summary
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
Official title: An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-12-03
Completion Date
2027-08
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
DRUG
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA
Locations (1)
Spectrum Neuroscience and Treatment Institute
New York, New York, United States